Company Insights

DCTH customer relationships

Explore interactive graphBrowse insights index
DCTH customer relationship map

Delcath Systems (DCTH): Customer Map and Commercial Implications for Investors

Delcath Systems sells and manufactures the HEPZATO™ KIT — a drug/device hepatic delivery system — and monetizes through direct sales and distribution agreements with major treatment centers in the United States and Europe. Revenue derives from device/drug kit sales to REMS-certified hospitals and from market penetration at high-volume oncology centers that adopt CHOPIN/CHemOSAT protocols. This customer footprint drives both short-term procedure revenue and longer-term optionality if protocol adoption broadens; see more on go-to-market implications at https://nullexposure.com/.

What the customer list tells investors about commercialization

Delcath’s customer mentions in public filings and press illustrate a focused, institution-based commercial rollout. The company manages sales and distribution directly in Europe and ships HEPZATO kits to hospitals under approved agreements in the U.S., which produces a seller/distributor contracting posture and concentrated counterparty exposure to major academic medical centers. According to company disclosures, HEPZATO received FDA approval on August 14, 2023, and the firm reports both manufacturing and distribution responsibilities across its single reportable segment (FY2025–FY2026 company filings).

  • Geographic focus is North America and EMEA, with active commercialization in both regions.
  • Contracting posture: direct sales plus distributor responsibilities in Europe create predictable revenue channels but concentrate operational risk around institutional adoption.
  • Maturity and criticality: early commercial stage — the product is approved and in use, but facility penetration remains limited to specialized centers, making each institutional relationship commercially important.

If you want a concise map of customer relationships and how they affect revenue risk, go to https://nullexposure.com/.

How adoption is progressing at leading centers

Delcath’s public commentary identifies a small set of high-profile adopters that function as both revenue sources and validation points for broader uptake.

MD Anderson — institutional validation in FY2025/Q4

MD Anderson is cited by Delcath as one of the named leading centers in the 2025 Q4 earnings call, underscoring its inclusion among REMS-certified treatment sites. According to the company’s 2025 Q4 earnings call, MD Anderson is listed alongside other major centers as part of Delcath’s certified network (2025 Q4 earnings call).

UT Southwestern — part of the certified treatment network

UT Southwestern is named in the same 2025 Q4 earnings call as a REMS-certified treatment site, indicating the hospital has the capability to treat with HEPZATO and contributes to procedure volume (2025 Q4 earnings call).

Mayo Clinic, Scottsdale — high-profile commercial anchor

Mayo Clinic, Scottsdale is explicitly listed in the company’s public remarks as a REMS-certified site, giving Delcath another marquee adoption point that supports referral flow and clinician familiarity (2025 Q4 earnings call).

UCLA — protocol adoption and clinical sequencing

UCLA is referenced for adopting CHOPIN-inspired protocols and flexible sequencing with combination agents, which signals institutional-level learning and protocol refinement that can increase procedure throughput (2025 Q4 earnings call and FY2026 coverage in an earnings transcript reposted by InsiderMonkey).

Massachusetts General Hospital — adoption of CHOPIN protocols

Massachusetts General Hospital is similarly highlighted for taking on CHOPIN-inspired protocols, indicating academic acceptance of procedural variations that may expand eligible patient cohorts (2025 Q4 earnings call; FY2026 news transcript).

Asklepios Hospital Barmbek (Hamburg) — European clinical outcomes publication

A retrospective clinical study published by Asklepios Hospital Barmbek (Hamburg) reported outcomes from 38 patients treated with Delcath’s CHEMOSAT system, demonstrating European clinical activity and academic validation in FY2025 as reported in a BioSpace press release (BioSpace, FY2025).

Quick, investor-friendly takeaways on each relationship

  • MD Anderson: Institutional adoption and REMS certification provide high-visibility validation and referral pipeline (company earnings call, 2025 Q4).
  • UT Southwestern: Part of the certified U.S. treatment network supporting procedure volume (company earnings call, 2025 Q4).
  • Mayo Clinic, Scottsdale: High-profile REMS-certified center, important commercially and reputationally (company earnings call, 2025 Q4).
  • UCLA: Active adopter of CHOPIN-inspired protocols; suggests clinical flexibility that increases addressable patients (earnings call; FY2026 transcript).
  • Massachusetts General Hospital: Academic adoption of protocols supports diffusion across elite centers (earnings call; FY2026 transcript).
  • Asklepios Hospital Barmbek: Published European single-center outcomes from repeated procedures, evidencing clinical experience with CHEMOSAT in FY2025 (BioSpace, FY2025).

Constraints and what they mean for commercial risk and upside

Company-level signals in public filings and disclosures define the operating model and risk posture:

  • Geography (NA & EMEA): Delcath operates primarily in the United States and Europe, so regulatory, reimbursement, and referral dynamics in both regions are material to revenue. This dual-region focus drives complexity but diversifies market exposure.
  • Roles — seller, distributor, manufacturer: The company manufactures the device/drug kit, sells directly to hospitals, and assumes distribution responsibilities in Europe. That vertical control improves margin capture but increases operational leverage and execution risk.
  • Relationship stage — active: Delcath reported active treatment sites and centers accepting referrals (16 facilities had treated patients as of March 5, 2025; 22 centers accepting referrals as of December 31, 2024), indicating early commercial traction but still low penetration relative to the total oncology market.
  • Segments — core product, distribution, manufacturing: HEPZATO is the lead, revenue-critical product; Delcath’s business model depends on continued clinical uptake and repeat procedures for sustained revenue growth.

These constraints translate into clear investor implications: concentration risk around key academic centers, execution risk tied to manufacturing and distribution scale-up, and upside linked to broader protocol adoption that increases eligible patient throughput.

For a concise institutional customer map and commercial risk dashboard, visit https://nullexposure.com/.

Bottom line: concentrated institutional adoption with measured upside

Delcath’s customer base today is concentrated among major academic medical centers that provide both revenue and clinical validation. The commercial thesis is straightforward: convert clinical adoption at leading centers into a repeatable procedure business while scaling distribution in EMEA and the U.S. Key risks are concentration, the early stage of commercial penetration, and the operational demands of manufacturing and distributing a drug/device combination product. Investors should watch procedure volumes at the named centers, additional REMS certifications, and European publication-driven adoption as the primary indicators of revenue trajectory.

If you want a deeper institutional relationship analysis or monitoring feed for Delcath customers, see the services available at https://nullexposure.com/.